Utilizing this foundational technique, CAR-T trials targeting CD3, CD5, CD7, TRBC1, and CCR4 are ongoing and possess immense potential in the treatment of T-cell lymphomas. The gene discussed is TRBC1; the disease is T-cell non-Hodgkin lymphoma.